Sign In
Buy RXRX
$3.52
+0.180 (+5.39%)
At Close: Jun 26, 2026
Recursion Pharmaceuticals (NASDAQ:RXRX) Insider Najat Khan Sells 124,403 Shares
05:03am, Tuesday, 30'th Dec 2025
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX - Get Free Report) insider Najat Khan sold 124,403 shares of the firm's stock in a transaction that occurred on Monday, December 22nd. The stock was sold
3 Small AI Plays to Buy for 2026
01:28pm, Friday, 26'th Dec 2025
Wall Street is ending 2026 on a generally positive note, with the benchmark S&P 500 Index set to finish the year at a 17% return rate. All eyes are now on technology titans like Nvidia, Microsoft, Alp
The Genesis Mission Has a 270-Day Timeline – And You’re Already Late
12:00am, Saturday, 20'th Dec 2025
The government is taking equity stakes in American companies. Here are the next Genesis Mission stocks to buy before the capital hits.
Miss These Genesis Mission Stocks, and You’ll Regret It for a Decade
12:00am, Saturday, 20'th Dec 2025
The government is taking equity stakes in American companies. Here are the next Genesis Mission stocks to buy before the capital hits.
Cathie Wood Keeps Dumping Tesla Stock -- Here is Why
07:33am, Friday, 19'th Dec 2025
Cathie Wood's ARK Invest once again trimmed its stake in Tesla (TSLA) while increasing exposure to crypto-related stocks, according to a Thursday filing with th
Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025
11:38am, Thursday, 18'th Dec 2025
Recursion Pharmaceuticals, Inc. is upgraded to Buy, supported by promising REC-4881 data and strong institutional backing. REC-4881's Phase 1b/2 data in FAP show a 43% median polyp reduction, deriskin
What's Happening With RXRX Stock?
11:05am, Thursday, 18'th Dec 2025
Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However
Recursion Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RXRX)
01:46am, Thursday, 18'th Dec 2025
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Stock investors purchased 37,151 call options on the company.
Cathie Wood's Big Crypto Bet: Ark Scoops Up Bitmine, Coinbase As Bitcoin, Ethereum Continue To Bleed, Dumps This Amazon Rival
09:28pm, Wednesday, 17'th Dec 2025
Cathie Wood-led Ark Invest executed several significant trades on Wednesday, with notable activity in Bitmine Immersion Technologies Inc (ASE: BMNR), Coinbase Global Inc (NASDAQ:
Why Recursion Pharmaceuticals Stock Vaulted 11% Higher on Wednesday
05:07pm, Wednesday, 17'th Dec 2025
One analyst tracking the biotech upgraded her recommendation on its shares. She now believes that they rate a buy, rather than a hold.
Why Recursion Pharamaceuticals Topped the Market Today
05:10pm, Monday, 08'th Dec 2025
The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing.
Recursion Pharmaceuticals, Inc. (RXRX) Discusses Updated Safety and Efficacy Data from TUPELO Phase I/II Study of REC-4881 in FAP Transcript
Why Are Shares Of Recursion Pharmaceuticals Higher Today?
10:48am, Monday, 08'th Dec 2025
Shares of Recursion Pharmaceuticals are trading higher Monday after the company reported positive data from an ongoing trial.
Recursion Pharma's AI-powered therapy reduces colon growth in a rare disease trial
07:32am, Monday, 08'th Dec 2025
Recursion Pharma , which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in patients with a rare gen
SALT LAKE CITY, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical-stage TechBio company decoding biology to radically improve lives, today announced positive Phase 1b/2 data from
